Resolving phlegm

"Resolving phlegm" is not a specific molecular target, receptor, or enzyme, but rather a therapeutic objective or physiological process involving the removal of excess mucus from the respiratory tract. In clinical pharmacology, this action is typically facilitated by two main classes of drugs: expectorants, which increase the hydration of airway secretions to make them easier to cough up, and mucolytics, which chemically degrade the mucin polymers (such as MUC5AC and MUC5B) to reduce mucus stickiness and viscosity (StatPearls, "Expectorants and Mucolytic Agents", 2023). This process is vital for managing respiratory diseases like chronic bronchitis, COPD, and cystic fibrosis, where mucus hypersecretion can lead to airway obstruction and secondary infections (NIH, PubMed). Because the term describes a broad pharmacological effect rather than a discrete biological molecule, it is classified as a therapeutic category rather than a specific drug target.

Other names

Expectorant actionMucolytic actionMucus clearancePhlegm resolutionTan-resolving

Drugs achieve phlegm resolution by reducing mucus viscosity (mucolytics), increasing the volume of airway secretions to facilitate coughing (expectorants), or enhancing the movement of the mucociliary escalator (mucokinetic agents).